Literature DB >> 31389187

Facilitating screening of Klinefelter syndrome among patients with diabetes.

Yohei Seno1, Yorihiro Iwasaki1, Megumi Aizawa-Abe1, Kanako Iwasaki1, Satoshi Yoshiji1, Sachiko Honjo1, Akihiro Hamasaki1.   

Abstract

Klinefelter syndrome (KS) is frequently complicated by diabetes. However, it is severely underdiagnosed due to a lack of reliable screening methods. We diagnosed two patients with KS at the Center for Diabetes and Endocrinology, Tazuke Kofukai Medical Research Institute Kitano Hospital, Osaka, Japan. By comparing the patients with 39 non-KS patients with diabetes, we propose a screening tool for KS in patients with diabetes.
© 2019 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31389187      PMCID: PMC7078131          DOI: 10.1111/jdi.13113

Source DB:  PubMed          Journal:  J Diabetes Investig        ISSN: 2040-1116            Impact factor:   4.232


Klinefelter syndrome (KS) is the most common male sex chromosomal aneuploidy. KS is severely underdiagnosed, however, partly due to the lack of a systematic screening method1. Here, we present two index cases of KS who were diagnosed at the Center for Diabetes and Endocrinology, Tazuke Kofukai Medical Research Institute Kitano Hospital, Osaka, Japan. Furthermore, to improve the screening efficiency of KS in diabetes clinics, we examined physical and endocrinological data non‐elderly adults with diabetes.

Case 1

A 40‐year‐old man was admitted to our department for glycemic control. He had a 6‐year history of poorly controlled diabetes. He was of tall stature (height 188.4 cm, bodyweight 97.5 kg), and his testes were bilaterally small. We found decreased serum total testosterone (0.76 ng/mL), elevated gonadotropin (luteinizing hormone [LH] 27.8 mIU/mL, follicle‐stimulating hormone 22.9 mIU/mL) and low human chorionic gonadotropin‐stimulated total testosterone level (0.76 ng/mL). KS was suspected, and G‐band karyotyping showed 47, XXY. Testosterone enanthate was initiated, and diabetes was well controlled with insulin degludec and dulaglutide.

Case 2

A 33‐year‐old man with newly diagnosed diabetes was admitted to our department for glycemic control. He had been married for 6 years with no children. He had a tall stature (height 188.0 cm, bodyweight 101.6 kg) and small testes. He showed a marked decrease in serum total testosterone (0.91 ng/mL), and elevated gonadotropin (LH 30.0 mIU/mL, follicle‐stimulating hormone 25.7 mIU/mL). Human chorionic gonadotropin‐stimulated total testosterone level was low (2.18 ng/mL). G‐band karyotyping showed 47, XXY, diagnostic of KS. Testosterone enanthate was initiated, and diabetes was treated with metformin and teneligliptin. He was also referred to an infertility clinic for assisted reproduction.

Analysis

To develop an efficient screening method for KS among patients with diabetes, we compared physical and endocrinological data from 39 non‐elderly (aged <60 years) Japanese male non‐KS patients with diabetes admitted to our center from July 2017 to April 2018 with those of the KS patients. The study was approved by the local ethics committee, and conforms to the principles of the Declaration of Helsinki. KS patients tended to be taller than non‐KS patients (Figure 1a). LH and follicle‐stimulating hormone were higher in KS patients compared with non‐KS patients (Figure 1b,c). Total testosterone was lower in KS patients (Figure 1d). Among several parameters, apparently the LH/total testosterone ratio is the most reliable index for distinguishing KS patients from non‐KS patients with diabetes (Figure 1e).
Figure 1

(a) Physical and (b–e) endocrinological data including height, luteinizing hormone (LH), follicle‐stimulating hormone (FSH), total testosterone and the LH/total testosterone ratio obtained from non‐elderly diabetes patients with or without Klinefelter syndrome (KS). Open circles represent data of diabetes patients without KS, and closed diamonds represent those of KS patients.

(a) Physical and (b–e) endocrinological data including height, luteinizing hormone (LH), follicle‐stimulating hormone (FSH), total testosterone and the LH/total testosterone ratio obtained from non‐elderly diabetes patients with or without Klinefelter syndrome (KS). Open circles represent data of diabetes patients without KS, and closed diamonds represent those of KS patients.

Discussion

KS is the most common male sex chromosomal aneuploidy, with an estimated prevalence of one in 600 births. KS is complicated by diabetes, with the estimated frequency of 10–39% in Western countries2. Although there are no large cohort studies in Japan, according to a literature review, the prevalence of diabetes among KS might be lower, at 3.9–4.1%3. KS can also be associated with an increased risk of type 1 diabetes4. There are several possible explanations for the increased risk of diabetes among KS. First, androgen deficiency is associated with impaired insulin sensitivity among patients with diabetes5. Second, in a murine model, ablation of androgen receptor in pancreatic β‐cells leads to a decreased glucose‐induced insulin secretion6. In addition to these direct effects on glucose metabolism, KS patients often have learning disabilities2, which could affect their glycemic control. In the present study, we found that the combination of physical (height) and endocrinological (LH/total testosterone ratio) parameters can efficiently differentiate KS patients from non‐KS patients with diabetes. To facilitate screening of KS among patients with diabetes, we propose a three‐step approach: the first step is careful physical examination of all non‐elderly male patients, especially those with poorly controlled diabetes, focusing on the characteristics of KS, including tall stature and small testes. The second step is endocrinological examinations including testosterone and gonadotropins. If the LH/total testosterone ratio is high, then we should carry out a human chorionic gonadotropin test and G‐band karyotyping for diagnosis. Although further studies are required, this approach might diminish the number of undiagnosed KS patients in diabetes clinics. Early diagnosis of KS in diabetes clinics will greatly benefit patients. First, it would offer KS patients access to well‐established assisted reproductive techniques7. Second, testosterone replacement might improve insulin sensitivity and insulin secretion in androgen‐deficient patients and animal models5, 6. In conclusion, the present data provide an efficient screening strategy to identify undiagnosed KS patients in diabetes clinics.

Disclosure

The authors declare no conflict of interest.

Acknowledgment

This work was supported by scientific research grants from the Ministry of Education, Culture, Sports and Technology, Japan (JSPS KAKENHI Grant Number 16K09772).
  7 in total

1.  Morbidity in Klinefelter syndrome: a Danish register study based on hospital discharge diagnoses.

Authors:  Anders Bojesen; Svend Juul; Niels H Birkebaek; Claus H Gravholt
Journal:  J Clin Endocrinol Metab       Date:  2006-01-04       Impact factor: 5.958

Review 2.  Screening for Klinefelter syndrome.

Authors:  Amy S Herlihy; Robert I McLachlan
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-06       Impact factor: 3.243

Review 3.  Diabetes mellitus associated with Klinefelter's syndrome: a case report and review in Japan.

Authors:  Kikuko Ota; Tadashi Suehiro; Yukio Ikeda; Kaoru Arii; Yoshitaka Kumon; Kozo Hashimoto
Journal:  Intern Med       Date:  2002-10       Impact factor: 1.271

4.  Success of testicular sperm extraction [corrected] and intracytoplasmic sperm injection in men with Klinefelter syndrome.

Authors:  Jonathan D Schiff; Gianpiero D Palermo; Lucinda L Veeck; Marc Goldstein; Zev Rosenwaks; Peter N Schlegel
Journal:  J Clin Endocrinol Metab       Date:  2005-08-30       Impact factor: 5.958

5.  Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men With Type 2 Diabetes.

Authors:  Sandeep Dhindsa; Husam Ghanim; Manav Batra; Nitesh D Kuhadiya; Sanaa Abuaysheh; Sartaj Sandhu; Kelly Green; Antoine Makdissi; Jeanne Hejna; Ajay Chaudhuri; Mark Punyanitya; Paresh Dandona
Journal:  Diabetes Care       Date:  2015-11-29       Impact factor: 19.112

6.  Extranuclear Actions of the Androgen Receptor Enhance Glucose-Stimulated Insulin Secretion in the Male.

Authors:  Guadalupe Navarro; Weiwei Xu; David A Jacobson; Barton Wicksteed; Camille Allard; Guanyi Zhang; Karel De Gendt; Sung Hoon Kim; Hongju Wu; Haitao Zhang; Guido Verhoeven; John A Katzenellenbogen; Franck Mauvais-Jarvis
Journal:  Cell Metab       Date:  2016-04-28       Impact factor: 27.287

Review 7.  Clinical review: Klinefelter syndrome--a clinical update.

Authors:  Kristian A Groth; Anne Skakkebæk; Christian Høst; Claus Højbjerg Gravholt; Anders Bojesen
Journal:  J Clin Endocrinol Metab       Date:  2012-11-01       Impact factor: 5.958

  7 in total
  1 in total

Review 1.  Glucose metabolic disorder in Klinefelter syndrome: a retrospective analysis in a single Chinese hospital and literature review.

Authors:  Tao Yuan; Weigang Zhao; Shixuan Liu; Shuoning Song; Shi Chen; Linjie Wang; Yong Fu; Yingyue Dong; Yan Tang
Journal:  BMC Endocr Disord       Date:  2021-12-01       Impact factor: 2.763

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.